Department of Neurosurgery, University of Technology, Fetscherstr. 74, 01307, Dresden, Germany.
Acta Neurochir (Wien). 2013 Mar;155(3):379-87. doi: 10.1007/s00701-012-1606-8. Epub 2013 Jan 13.
Metastases are the most frequent tumours in the brain. At the time of diagnosis, more than 50% of patients present with multiple lesions. The goal of our retrospective investigation was to evaluate the outcome of patients who undergo surgery for multiple cerebral metastases and to determine prognostic factors.
We included 127 patients with multiple brain metastases in the study. The median number of metastases was three. All patients were operated on for at least one lesion. The indications for surgery were: large tumours ≥27 cm(3), metastases of unknown primaries at the time of diagnosis, and space-occupying cerebellar lesions. If possible, adjuvant WBRT was applied.
The median MST of the whole group was 6.5 months; for patients with complete resection, 10.6 months. According to the RPA classification the MST ranged between 19.4 (class I), 7.8 (class II), and 3.4 months (class III) (p < 0.001). KPS > 70 had a significant influence on MST (9.1 months vs. 3.4 months, p < 0.001), the number of lesions: 2-4 vs. >4 (p = 0.046), and postoperative WBRT in multivariate analysis (p = 0.026). Age was not a significant factor. The 2-year survival rate was 15% and the 3-year survival rate 10%.
Favourable factors for prolonged survival were complete resection of all lesions, no more than four metastases, RPA-class I and adjuvant WBRT. The resection of large lesions, while leaving smaller residual ones, did not result in increased survival.
转移瘤是脑内最常见的肿瘤。在诊断时,超过 50%的患者存在多发病灶。我们回顾性研究的目的是评估接受多发性脑转移瘤手术的患者的预后,并确定预后因素。
我们将 127 例多发性脑转移瘤患者纳入本研究。转移灶的中位数为 3 个。所有患者至少有一个病灶接受手术治疗。手术的适应证为:肿瘤直径≥27cm³、诊断时原发灶不明的转移瘤和占位性小脑病变。如果可能,辅助全脑放疗(WBRT)。
全组患者的中位总生存期(MST)为 6.5 个月;完全切除患者的 MST 为 10.6 个月。根据 RPA 分类,MST 范围为 19.4(I 级)、7.8(II 级)和 3.4 个月(III 级)(p<0.001)。卡氏功能状态评分(KPS)>70 对 MST 有显著影响(9.1 个月比 3.4 个月,p<0.001),病变数量:2-4 个比>4 个(p=0.046),术后 WBRT 在多因素分析中(p=0.026)。年龄不是一个显著因素。2 年生存率为 15%,3 年生存率为 10%。
延长生存的有利因素包括所有病灶的完全切除、不超过 4 个转移灶、RPA 分级 I 级和辅助 WBRT。切除大病灶,同时留下较小的残留病灶,并不会导致生存时间延长。